Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:25:26 EDT Sun 15 Mar 2026
Enter Symbol
or Name
USA
CA



Q:DBVT - DBV TECHNOLOGIES SPON ADS EACH REPR 5 ORD SHS (R/S) - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DBVT - Q0.215.30·36.000.120.53+0.472.3400.18,0611,75721.49  21.49  20.0526.185  3.9116:00:14Mar 0415 min RT 2¢

Recent Trades - Last 10 of 1757
Time ETExPriceChangeVolume
16:00:14Q20.530.471
16:00:14Q20.530.471
16:00:04Q20.530.4734
16:00:04Q20.530.47346
16:00:02Q20.530.47518
16:00:02Q20.530.4737
16:00:02Q20.530.4737
16:00:02Q20.530.4737
16:00:02Q20.530.4737
16:00:02Q20.530.4737

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-04 16:30U:DBVTNews ReleaseDBV Technologies to Participate in Upcoming March Investor Conferences
2026-03-03 16:30U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
2026-02-28 14:25U:DBVTNews ReleaseDBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
2026-02-10 16:30U:DBVTNews ReleaseDBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN(TM) Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
2026-02-09 16:30U:DBVTNews ReleaseDBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
2026-02-05 16:30U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
2026-01-16 18:11U:DBVTNews ReleaseDBV Technologies Announces euros166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
2026-01-12 16:00U:DBVTNews ReleaseInformation Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
2026-01-07 16:00U:DBVTNews ReleaseHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
2026-01-05 16:00U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
2025-12-16 16:05U:DBVTNews ReleaseDBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN(TM) Peanut Patch in Peanut Allergic Children Aged 4-7 Years
2025-12-02 16:00U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
2025-11-11 23:50U:DBVTNews ReleaseDBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN(TM) Peanut Patch in Peanut Allergic Children Aged 4-7 Years
2025-11-04 16:30U:DBVTNews ReleaseDBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-11-03 16:30U:DBVTNews ReleaseDBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
2025-11-03 16:25U:DBVTNews ReleaseInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
2025-10-30 16:30U:DBVTNews ReleaseDBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
2025-10-30 03:00U:DBVTNews ReleaseDBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
2025-10-29 18:47U:DBVTNews ReleaseDBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
2025-10-28 16:25U:DBVTNews ReleaseDBV Technologies Reports Third Quarter 2025 Financial Results